Exact Sciences

The company operates across three oncology nodes: screening (Cologuard and Cologuard Plus for colorectal cancer), therapy guidance (Oncotype DX tests for breast, colon, and DCIS recurrence risk and chemotherapy benefit), and precision medicine (OncoExTra for comprehensive genomic profiling of solid tumors). The Riskguard hereditary cancer test, acquired through PreventionGenetics in 2022, adds hereditary risk assessment (per the firm's product pages).

The BLUE-C study, published in 2024, served as the pivotal validation for Cologuard Plus, the next-generation stool-DNA colorectal cancer screening test. The study compared the updated assay against colonoscopy in a large prospective cohort, providing the clinical evidence needed to support FDA submission and large-scale commercial adoption (per the firm's public releases). Results are expected to drive physician adoption rates for the upgraded test.

In screening, the firm competes against colonoscopy providers and other non-invasive stool-based tests, though no single named competitor dominates the labeled indication. In therapy guidance, Agendia (MammaPrint) and Veracyte offer overlapping breast cancer gene-expression tests. For comprehensive genomic profiling, Guardant Health and Foundation Medicine operate larger pan-cancer platforms with broader biomarker panels and established oncologist ordering patterns.

Prevention sits upstream of every other business line: Cologuard and Cologuard Plus screen asymptomatic average-risk individuals for colorectal cancer, while the Riskguard test identifies germline mutations that elevate lifetime cancer risk. This creates a testing funnel that can feed patients into the Oncotype DX therapy-guidance franchise and the OncoExTra therapy-selection assay after diagnosis.

The company operates its own CLIA-certified laboratories, with primary facilities in Madison, Wisconsin. In-source lab operations give it control over turnaround time, assay iteration, and margin structure, though this model requires sustained capital expenditure for capacity expansion as test volumes grow.